Literature DB >> 23714793

Fibrous dysplasia of the zygomaticomaxillary region: outcomes of surgical intervention.

Joubin S Gabbay1, Joyce T Yuan, Brian T Andrews, Henry K Kawamoto, James P Bradley.   

Abstract

BACKGROUND: Fibrous dysplasia is the most common craniofacial tumor, presenting in both monostotic and polyostotic forms with varying degrees of severity. No consensus exists regarding the surgical management of craniofacial fibrous dysplasia, particularly in the zygomaticomaxillary region. The present study compared long-term outcomes of limited reduction burring versus radical resection of zygomaticomaxillary fibrous dysplasia.
METHODS: Patients with craniofacial fibrous dysplasia at the University of California, Los Angeles, Craniofacial Center from 1982 to 2008 were studied based on demographics, treatment, and follow-up data, including examinations, computed tomographic scans, photographs, physician Whitaker scoring, and patient surveys (n=97). Outcomes were compared for zygomaticomaxillary disease treated with radical resection with cranial bone graft reconstruction or limited reduction burring (n=58).
RESULTS: Thirty-four percent of patients had monostotic disease, 66 percent had polyostotic disease, 3 percent had McCune-Albright syndrome, and 2.1 percent had malignant degeneration into osteosarcoma. Most patients had surgical treatment (84.5 percent). Of the patients that required optic nerve decompression for vision changes (11.4 percent), most (75 percent) had vision stabilization postoperatively. Differences were recorded in zygomaticomaxillary disease treated with radical resection (63.8 percent) versus reduction burring (36.2 percent) according to age (19.6 versus 14.2 years), complications (13.5 percent versus 4.8 percent), recurrence (66.7 percent versus 24.3 percent), and number of subsequent procedures (2.8 versus 4.0). There were similarities in Whitaker outcome score (1.3±0.3 versus 1.5±0.6) and patient satisfaction (2.7±0.4 versus 2.8±0.3).
CONCLUSIONS: Although different approaches have been advocated to treat fibrous dysplasia, the authors' data support a more aggressive management for zygomaticomaxillary disease with radical resection and cranial bone graft reconstruction, especially for more involved disease. CLINICAL QUESTION OF EVIDENCE: Therapeutic, III.

Entities:  

Mesh:

Year:  2013        PMID: 23714793     DOI: 10.1097/PRS.0b013e31828bd70c

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  5 in total

Review 1.  Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives.

Authors:  Cemre Robinson; Michael T Collins; Alison M Boyce
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

2.  Our experience in the surgical management of craniofacial fibrous dysplasia: what has changed in the last 10 years?

Authors:  V Valentini; A Cassoni; V Terenzi; M Della Monaca; M T Fadda; O Rajabtork Zadeh; I Raponi; A Anelli; G Iannetti
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-10       Impact factor: 2.124

3.  Surgical Management of Polyostotic Craniofacial Fibrous Dysplasia: Long-Term Outcomes and Predictors for Postoperative Regrowth.

Authors:  Alison M Boyce; Andrea Burke; Carolee Cutler Peck; Craig R DuFresne; Janice S Lee; Michael T Collins
Journal:  Plast Reconstr Surg       Date:  2016-06       Impact factor: 4.730

4.  Gigantism in a McCune-Albright's syndrome with calcified GH-releasing pituitary adenoma: Case report and literature review.

Authors:  Miguel Vega-Arroyo; Martha Lilia Tena-Suck; Celia Teresa de Jesús Álvarez-Gamiño; Citlaltepetl Salinas-Lara; Juan Luis Gómez-Amador
Journal:  Int J Surg Case Rep       Date:  2018-10-23

5.  Case Report: A Neuro-Ophthalmological Assessment of Vision Loss in a Pediatric Case of McCune-Albright Syndrome.

Authors:  Jordan D Lemme; Anthony Tucker-Bartley; Laura A Drubach; Nehal Shah; Laura Romo; Mariesa Cay; Stephan Voss; Neha Kwatra; Leonard B Kaban; Adam S Hassan; Alison M Boyce; Jaymin Upadhyay
Journal:  Front Med (Lausanne)       Date:  2022-03-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.